Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ophthalmic, Healthy Eyes Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

NCT02658435
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 150 mg, Matched placebo 150mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Glendale, California • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 21, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Coherence Tomography (OCT) Normative Data Collection Study

NCT02014688
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00569777
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
K-Lens (generic name not established) and Ketotifen, Placebo Lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Gardena, California • North Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

NCT00414999
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy
Interventions
TG100801
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2007 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

NCT01531699
View directory record Official record
Conditions
Infection Secondary to Surgical Procedure
Interventions
ALT005 Ophthalmic Prep Solution, saline control, Betadine ophthalmic prep solution
Drug · Other
Lead sponsor
Altacor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety Evaluation of a New Preservative in a Lubricating Eye Drop

NCT01434277
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Eye Drops with Experimental Preservative
Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

NCT03063489
View directory record Official record
Conditions
Eye Pain
Interventions
Loteprednol Etabonate Ophthalmic Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 21, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Test-Retest Variability of Quick Contrast Sensitivity Function Testing

NCT02177669
View directory record Official record
Conditions
Healthy
Interventions
quick Contrast Sensitivity Function test
Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
20 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

NCT01736527
View directory record Official record
Conditions
Pharmacokinetics
Interventions
LE Gel
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 21, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

TopQ Cut-Off Determination Study

NCT01824784
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 21, 2026, 2:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

NCT06674941
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

NCT02033668
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 21, 2026, 2:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Relationships Among Pupil Responses to Light, Circadian Rhythms, and Sleep

NCT07753889
View directory record Official record
Conditions
Circadian Rhythm, Pupillometry, Sleep
Interventions
Ocular light exposure from portable light box
Other
Lead sponsor
Elizabeth B Klerman MD PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Factors in Learning And Plasticity: Healthy Vision

NCT05439759
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

NCT01997879
View directory record Official record
Conditions
Healthy
Interventions
AR-13324 Ophthalmic Solution, 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engineering Evaluation of an Eye Movement Monitor Device

NCT05222022
View directory record Official record
Conditions
Healthy
Interventions
Retitrack
Device
Lead sponsor
C. Light Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

NCT01736462
View directory record Official record
Conditions
Corneal Endothelial Cell Changes
Interventions
Mapracorat
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

NCT02167594
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

NCT05729594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 21, 2026, 2:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli

NCT06961864
View directory record Official record
Conditions
Visual Snow Syndrome, Migraine, Healthy
Interventions
Visual Adaptation, Assessments and Questionnaires, Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Imaging (MRS)
Behavioral · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
View directory record Official record
Conditions
Atopic Disease (Including Allergic Conjunctivitis)
Interventions
Drug: AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 21, 2026, 2:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ClearPath DS-120 Clinical Study Protocol

NCT01425346
View directory record Official record
Conditions
Ophthalmic, Healthy Eyes
Interventions
Not listed
Lead sponsor
Freedom Meditech
Industry
Eligibility
21 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 21, 2026, 2:41 PM EDT